Valerie Byrnes

A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease

Detlef Schuppan, Markku Mäki, Knut E. A. Lundin et al. · New England Journal of Medicine · 2021 · 206 citations · Full text

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease

Joseph A. Murray, Ciarán P. Kelly, Peter H.R. Green et al. · Gastroenterology · 2016 · 131 citations · Full text

Difference Between Latiglutenase, Villous Atrophy, Clinical Presentation +3

Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition

Valerie Byrnes, Anne Miller, Damien Lowry et al. · Journal of Hepatology · 2011 · 101 citations

Neuropsychology, Cerebral Metabolism, Antiviral Drug +16

Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study

Christophe Cellier, Gerd Bouma, Tom van Gils et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 96 citations · Full text

Gastroenterology, Clinical Trials, Type 2 +5

The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease

Raza Malik, Michael Y. Chang, Killimangalam Bhaskar et al. · Journal of Gastroenterology and Hepatology · 2009 · 83 citations